Emmecell Appoints Ramin Valian as CEO

Emmecell, a clinical-stage biotechnology company pioneering magnetic cell delivery technologies for ophthalmic disease, has appointed Ramin Valian as Chief Executive Officer (CEO).

As CEO, Valian will oversee corporate strategy, clinical and regulatory development, partnerships, and operational growth as the company prepares for pivotal cornea trials and commercialization.

Experience

A veteran biopharmaceutical executive, Valian brings over 20 years of global commercial and strategic leadership in eye care, with expertise spanning corneal disease, surgical and interventional glaucoma, retina, and consumer eye care. He has successfully led the launch of six ophthalmic products across therapeutics and medical technologies.

Valian joins Emmecell following a career at Allergan and AbbVie, where he played key roles in global strategy, clinical development, and commercialization of high-impact ophthalmic products.

“I believe Emmecell’s magnetic cell delivery technology has the potential to fundamentally redefine ophthalmic treatment—from corneal disease to geographic atrophy,” said Valian. “The ability to precisely and non-invasively position therapeutic cells opens new possibilities for regenerative medicine. I’m honored to lead Emmecell as it advances toward pivotal clinical development and commercialization.”